natgillin/translations-raw huggingface dataset:
the IMP cell is capable of migrating to, adhering to, proliferating in, having anti-inflammatory effects in and/or promoting angiogenesis in a specific, damaged tissue in a patient; 
(a) IMP stanica je sposobna migrirati do, prianjati na, razmnožavati se u, ispoljavati protuupalne učinke na i/ili potpomagati angiogenezu u specifičnom, oštećenom tkivu pacijenta;
feeding into the mixer the mass to be treated, 
dodavanja u miješalicu mase koju treba obraditi,
reducing the expression or activity of a DA2 polypeptide within cells of said plant, wherein the DA2 polypeptide comprises a RING domain of SEQ ID NO: 2 and the plant has reduced DA1 or reduced DA1 and EOD1 expression or activity, wherein the expression or activity of the DA2 polypeptide is reduced by 
Postupak prema zahtjevu 1, naznačen time, da obuhvaća smanjivanje ekspresije ili aktivnosti polipeptida DA1 i/ili polipeptida EOD unutar stanica navedene biljke; pri čemu se ekspresija 1li aktivnost polipeptida DA1 ili polipeptida EOD smanjuje pomoću sljedećeg:
The composition of any one of claims 7-11, wherein the rasagiline citrate is mixed with a polymer. The composition of any one of claims 7-12, further comprising stearic acid. 
Sastav prema jednom od patentnih zahtjeva 7-11, naznačen time, da je rasagilin citrat pomiješan s polimerom Sastav prema jednom od patentnih zahtjeva 7-12, naznačen time, da nadalje sadrži stearinsku kiselinu.
reacting a compound having the formula II-A with a compound having the formula III in the presence carbonyldiimidazole or triphosgene and a base; or 
reakciji spoja koji ima formulu II-A sa spojem koji ima formulu III, u prisutnosti karbonildiimidazola ili trifozgena i baze; ili
A description of a method for determining the colour intensity is provided below. 
Opis postupka za određivanje intenziteta boje je dan niže.
The mixture was concentrated to give a foam product of Formula 42. 
Smjesa je bila koncentrirana da bi se dobila pjena produkta formule 42.
wherein the first data store further stores one or more of the first node master public key (P1C), the second node master public key (P1S), and the message (M); or 
Uređaj prema zahtjevu 12 naznačen time da prva pohrana podataka nadalje pohranjuje jedan ili više glavni javni ključ prvog čvora (P1C), glavni javni ključ drugog čvora (Pis), i poruku (M).
the compounds of formula: are disclaimed. A pharmaceutical composition comprising a compound of formula (Ia), or a pharmaceutically acceptable salt or ester thereof, in combination with a pharmaceutically acceptable excipient, diluent or carrier and optionally a second drug substance: wherein m is 1 or 2; 
Farmaceutski sastav, naznačen time, da obuhvaća spoj formule (Ia), ili njegovu farmaceutski prihvatljivu sol ili njegov farmaceutski prihvatljiv ester, u kombinaciji s farmaceutski prihvatljivim pomoćnim sredstvom, razrjeđivačem ili nosačem i opcijski sadrži drugu ljekovitu tvar: gdje mje 11li2;
is hydrogen, C1 to C6 alkyl, phenyl unsubstituted or substituted by C1 to C6 alkyl, COR6 acyl group (R6 being hydrogen; C1 to C6 straight chain or branched alkyl; phenyl or benzoyl respectively unsubstituted or substituted by C1 to C6 alkyl), or any group leading to hydroxyl upon biological metabolization or chemical deprotection; and salts thereof. 
Ru je vodik, C, do Cg alkil, fenil nesupstituiran ili supstituiran s C, do Cg alkilom, COR; acilnom skupinom (Rs je vodik; C; do Cg ravnolančani ili razgranati alkil; odnosno fenil ili benzoil nesupstituiran ili supstituiran s C, do Cy alkilom), ili bilo kojom skupinom koja vodi do hidroksila nakon biološke razgradnje ili kemijskog uklanjanja zaštite; i njegove soli; za uporabu u prevenciji 1/ili liječenju karcinoma prostate.
The compound of any one of claims 46-48, wherein Rp and Rr are each independently H, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, trifluoroethyl, methyl, ethyl, hydroxymethyl, hydroxyethyl, chloro, cyano, cyclopropyl, cyclobutyl, or cyclopentyl. 
Spoj prema patentnom zahtjevu 22, naznačen time, da Rp i Rr su svaki neovisno vodik, fluorometil, difluorometil, trifluorometil, fluoroetil, trifluoroetil, metil, etil, hidroksimetil, hidroksietil, kloro, cijano, ciklopropil, ciklobutil ili ciklopentil.
The invention is to be understood as including the compounds of the invention in free or salt form and, where possible, in acid addition salt form. 
U okviru izuma se podrazumijeva da on uključuje spojeve formule (1) i (Ia) u slobodnom obliku ili u obliku soli i, gdje je to moguće, u obliku kiselinske adicijske soli.
The present invention relates to 1-aza-bicycloalkyl derivatives of formula (1) wherein A represents O or N(R1); 
Spoj formule I M) naznačen time, da A predstavlja O ili N(R');
A process for obtaining a pharmaceutical composition containing glatiramer acetate, which comprises polymerizing N-carboxyanhydrides of tyrosine, alanine, Y-benzyl glutamate and trifluoroacetyl lysine to form protected glatiramer acetate; deprotecting the protected glatiramer acetate with a solution of hydrobromic acid in acetic acid, which solution has been pretreated with a bromine scavenger in order to remove free bromine, to form trifluoroacetyl glatiramer acetate; 
Postupak za dobivanje farmaceutskog sastava koji sadrži glatiramer acetat, naznačen time, da sadrži a) polimeriziranje N- karboksianhidrida od tirozina, alanina, y-benzil glutamata i trifluoracetil lizina da bi se formirao zaštićeni glatiramer acetat; b) skidanje zaštite sa zaštićenog glatiramer acetata otopinom bromovodične kiseline u octenoj kiselini, koja je otopina prethodno obrađena hvatačem broma radi uklanjanja slobodnog broma, da bi se formirao trifluoracetil glatiramer acetat;
Administration of ST2087 in the Rat (Table 1) 
Primjena ST2087 u štakora (Tablica 1)
only after receiving an affirmative acknowledgment, calling for the reading of the coded-identification means and cross-checking with a code previously acquired from the request enabling the user to conclude the drawing on the basis of the result of the cross-check. 
- < samo nakon dobivanja afirmativne potvrde, pozivanje na čitanje sredstva kodirane identifikacije i unakrsno ispitivanje s kodom koji je prethodno dobiven od zahtjeva koji omogućava da završi vađenje na temelju rezultata unakrsnog ispitivanja.
A pharmaceutical composition as claimed in claims 5 or 6, which comprises one or more additional agents selected from the group consisting of 3-APS, vitamin E, ginkgolide, donepezil, rivastigmine, tacrine, galantamine, memantine, NS-2330, ibutamoren mesylate, capromorelin, minocycline and rifampicin. 
Farmaceutski pripravak prema zahtjevima 5 ili 6, naznačen time da sadrži jedno ili više, dodatnih sredstava odabranih iz skupine koja sadrži Alzhemed, vitamin E, ginkolid, donepezil, rivastigmin, takrin, galantamin, memantin, NS-2330, ibutamoren mesilat, kapromorelin, minociklin i rifampicin.
The monoclonal antibody or antigen-binding fragment thereof according to claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof selectively inhibits the human CGRP receptor as compared with human AM1, AM2, and AMY1 receptors with a selectivity ratio of 100 or more as determined by a cAMP inhibition assay. 
Antitijelo ili njegov antigen-vežući fragment prema patentnim zahtjevima 1 ili 2, naznačeno time što je antitijelo ili antigen-vežući fragment odabrano iz grupe koja se sastoji od monoklonskog antitijela, Fab fragmenta, Fab’ fragmenta, F(ab’)2 fragmenta, Fv fragmenta, di-antitijela i jednolančanog antitijela.
is selected from optionally substituted heteroaryl having 5 to 15 ring atoms and optionally substituted aryl having 6 to 12 ring atoms, wherein the optional substituents on R2 groups are 1, 2 or 3 substituents independently selected from halogen, C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, C1-C4 thioalkoxy, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, sulfhydryl, cyano, C6 aryl and heteroaryl having 5 or 6 ring atoms; 
je odabran od po izboru supstituiranog heteroarila koji ima 5 do 15 atoma u prstenu i po izboru supstituiranog arila koji ima 6 do 12 atoma u prstenu, pri čemu su proizvoljni supstituenti na R2 skupinama 1, 2 ili 3 supstituenta neovisno odabrani iz niza koji čine halogen, C1-C4 alkil, halo-C1-C4 alkil, C1-C4 alkoksi, C1-C4 tioalkoksi, hidroksil, amino, C1-C4 alkilamino, C1-C4 dialkilamino, sulfhidril, cijano, C6 aril i heteroaril koji ima 5 ili 6 atoma u prstenu.
The process for synthesis of N-methyl-para-anisidine, consist in that N-alkylation of para-nitroanisole and/or para-anisidine is performed in vapor phase on dehydrogenating catalyst at a temperature 180-260°C and atmospheric pressure with subsequent product isolation using rectification. 
Postupak za sintezu N-metil-para-anisidina koji sadrži: N-alkiliranje para-nitroanisola i/ili para-anisidina u parnoj fazi na dehidrogeniranom katalizatoru odabranom iz skupine koju čine Raney nikla i katalizatora bakar-kroma modificiran oksidima barija, kalcija ili cinka na temperaturi od 180-260 °C i atmosferskim tlakom u struji vodika ili dušika s naknadnim izoliranjem proizvoda ispravljanja.
said antibody or fragment does not inhibit human IL-7 induced phosphorylation of STAT5 in cells expressing the IL7-R; 
navedeno antitijelo ili fragment ne inhibira fosforilaciju STATS induciranu humanim IL-7 u stanicama koje eksprimiraju IL7-R;
the subcutaneously volatile solvent is selected from the group consisting of glycerol formal, N-methylpyrrolidone (NMP), triacetin, dimethylacetamide, ethylacetamide, solketal, propylene carbonate, ethyl lactate, ethyl acetate, and mixtures thereof; 
Tekuća injektibilna formulacija s produljenim djelovanjem prema zahtjevu 1, naznačena time, da je supkutano hlapljivo otapalo odabrano iz skupine koju čine: N-metil-pirolidon (NMP), triacetin, dimetilacetamid, etilacetamid, etil-acetat i njihove mješavine.
For regeneration, the column was flushed with at least 6 BV of regeneration solution 1, followed by 10 BV of regeneration solution 2. 
Za regeneraciju, kolona se opere s najmanje 6 BV regeneracijske otopine, nakon čega s 10 BV regeneracijske otopine.
forming a first biphasic composition comprising (i) a first organic phase, and (ii) an alcoholic-caustic phase containing the trans-(-)-A9-tetrahydrocannabinol and the trans-(+)-A9-tetrahydrocannabinol; 
formiranja prvog bifaznog sastava koji sadrži (i) prvu organsku fazu, i (ii) alkoholno-kaustičnu fazu koja sadrži trans-(-)-A9-tetrahidrokanabinol i trans-(+)-A9-tetrahidrokanabinol;
A compound of formula (I) as defined in any one of claims 1 to 6, or the composition according to claim 7, for use in the prevention of bone loss, the attenuation of bone loss, the stimulation of bone growth, to produce an increase in bone density in a patient in need thereof and/or to treat or prevent disuse osteoporosis, or for use in the prevention or treatment of osteoporosis and/or osteopenia in a patient by: 
Tvar formule (I) kako je definirano u bilo kojem od patentnih zahtjeva 1 do 6, ili sastav u skladu s patentnim zahtjevom 7, za uporabu u prevenciji gubitka kostiju, umanjivanja gubitka kostiju, stimulaciji rasta kostiju, stvaranju povećane gustoće kostiju kod potrebitog pacijanta i/ili liječenju ili prevenciji osteoporoze mirovanja, ili za uporabu u prevenciji 1li liječenju osteoporoze i/ili osteopenije kod pacijanta na način:
The pharmaceutical composition according to claim 1 wherein the vaginal bacteria is selected from the group consisting of Gardnerella vaginalis, Mycoplasma hominis, Bacteroides Atopobium vaginale, Peptostreptococcus, Mobiluncus, Prevotella, Veillonella and mixtures thereof. 
Farmaceutski pripravak prema zahtjevu 1 naznačen time da je vaginalna bakterija odabrana iz skupine koju čine Gardnerella vaginalis, Mycoplasma hominis, Bacteroides Atopobium vaginale, Peptostreptococcus, Mobiluncus,
Ball-shaped surface modified calcium carbonate containing mineral obtained by drying the aqueous slurry of any one of claims 16 to 20, wherein the ball-shaped surface modified calcium carbonate containing mineral has a narrow particle size distribution d98/ d 50 of smaller than 3, and a median grain diameter of from 15 µm to 50 µm determined by Malvern Mastersizer. 
Površinski modificirani kalcijev karbonat koji sadrži mineral koji je dobiven sušenjem vodene suspenzije prema bilo kojem od zahtjeva 16 do 20, naznačen time da navedeni površinski modificirani kalcijev karbonat koji sadrži mineral ima BET specifičnu dodirnu površinu veću od 15 m2/g.
represents a hydrogen atom or a C1-6 alkyl group; represents a hydrogen atom, a C1-6 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom, a phenyl group, a hydroxyl group or a C1-6 alkoxy group; 
R4 predstavlja atom vodika ili C,.4 alkilnu skupinu; R5 predstavlja atom vodika, C,.4 alkilnu skupinu, izborno supstituiranu s 1 do 4 supstituenta, koje se bira između atoma halogena, fenilne skupine, hidroksilne skupine ili C,.s alkoksi skupine;
The lithium accumulator of claim 1 wherein the electrolyte further contains modification agents, improving accumulator functions at high temperatures and/or removing decomposing products and/or protecting the accumulator from overcharging and /or substances effecting the size of metal lithium dendrites. 
Litijski akumulator prema zahtjevu 1, u kojem elektrolit nadalje sadrži sredstva za modifikaciju, poboljšavajući akumulator od prekomjernog punjenja i/ili tvari koje djeluju na veličinu dendrita metala litija.
about 70% to about 80% by weight of a dimethylpolysiloxane elastomer; and 
od 70 % do 80 % dimetilpolisiloksan elastomera u odnosu na masu i
The compound of claim 1, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage, at least one modified sugar, or at least one modified nucleobase, optionally wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage. 
AcHN . Spoj prema zahtjevu 1, gdje modificirani oligonukleotid sadrži barem jednu modificiranu internukleozidnu vezu, barem jedan modificirani šećer, ili barem jednu modificiranu nukleobazu, opcionalno gdje modificirana internukleozidna veza je fosforotioatna internukleozidna veza.
The aqueous formulation of item 8 comprising 0.2 to 1 µg lixisenatide per U insulin glargine. 
Vodena formulacija u skladu s patentnim zahtjevom 3, naznačena time što sadrži 0,2 ug do 1 ug liksisenatida po jedinici inzulin glargina.
Other attempts have been made at improved forage inoculant-type application systems. 
Rađeni su i drugi pokušaji da se poboljšaju sustavi primjene inokulanata na krupnu stočnu hranu.
The compound or salt of claim 1 wherein m is selected from the group consisting of 0 and 1; 
Spoj ili sol prema zahtjevu 1, naznačen time, da je m odabran iz skupine koju čine 01 1;
The liquefied gas treatment system according to claim 4, wherein the boil-off gas supplied to the heat exchanger (21) is a boil-off gas compressed while passing through all or part of the plurality of compression means included in the compressor (13,13a,13b). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7 ili 8, naznačen time što je otpareni plin poslan u izmjenjivač topline (21) otpareni plin, koji se komprimira prilikom prolaska kroz sve ili dio od više kompresijskih cilindara (14) koje sadrži kompresor (13).
The system of claims 1-2 further comprising an ion pellet injector (700) coupled to the confinement chamber (100). 
Sustav prema zahtjevima 1 do 2, naznačen time, da dodatno obuhvaća ionski pelet-injektor (700) koji je spojen na priključnu komoru (100).
H-indazole-3-carboxamide for the use according to claim 14, wherein said spinal neurodegenerative disorders are selected from the group consisting of amyotrophic lateral sclerosis, multiple sclerosis, spinal muscular atrophy and neurodegeneration due to spinal cord injury. 
H-indazol-3-karboksamid za uporabu prema zahtjevu 14, naznačen time, da su navedeni spinalni neurođegenerativni poremećaji odabrani iz skupine koju čine amiotrofna lateralna skleroza, multipla skleroza, spinalna muskularna atrofija i neurođegeneracija zbog ozljede kralježnične moždine.
one or more other substances selected from a group consisting of: creatine, carnitine, gamma oryzanol, lipoic acid, choline, carnosine, phosphatidylserine, lutein, lycopene, resveratrol, other anti-oxidants, essential fatty acids omega-3 and/or omega-6, vegetable substances, extracts and/or preparations, such as extract of Blueberry, Ginseng, Ginkgo biloba, Rhodiola rosea, Boswellia serrata, yeast, xylitrol, erythritol, mannitol, sorbitol, amino acids, branched or modified amino acids. 
- < jednom ili više drugih tvari koje su odabrane iz skupine koju čine: kreatin, karnitin, gama orizanol, lipoična kiselina, kolin, karnozin, fosfatidilserin, lutein, likopen, resveratrol, drugi antioksidansi, esencijalne masne kiseline omega-3 i/ili omega-6, biljne tvari, ekstrakti i/ili pripravci, kako što su ekstrakt borovnice, Ginsenga, Ginkgo bilobe, Rhodiola rosea, Boswellia serrata, kvasac, ksilitrol, eritritol, manitol, sorbitol, amino kiseline, razgranate ili modificirane amino kiseline.
a coupling mechanism (700) for releasably coupling said first ring member to said second ring member, to allow said first and second ring members to rotate cooperatively when coupled and to allow independent rotating of said first ring member when not coupled; 
Brojač kao što je navedeno u zahtjevu 1 dalje sadržeći mehanizam sparivanja (700) za odvojivo sparivanje navedenog prvog prstenastog elementa (201) s navedenim drugim prstenastim elementom (202, 1510), kako bi se omogućilo navedenim prvom i drugom prstenastom elementu da kooperativno rotiraju kad spareni te kako bi se omogućilo samostalno rotiranje navedenog prvog prstenastog elementa kad nije sparen.
In its 6-membered pyranose form, fructose is more likely to form a bond, to a drug, for example, through the single primary alcohol that is present at the 1 position in the pyranose form. 
U svojem 6-članom piranoznom obliku, fruktoza će vjerojatnije stvarati vezu s lijekom, na primjer, kroz jedinstveni primarni alkohol koji je prisuatn na položaju 1 piranoznog oblika.
A process for the recrystallization of a compound of formula (I-S) comprising 
PATENTNI ZAHTJEVI 1. Postupak za rekristalizaciju spojeva formule (I-S)
The system of claim 6, wherein the at least one of the at least two pump segments (103) comprises a first pump segment (103a) and wherein the at least one other pump segment comprises a second pump segment (103b) and wherein respective peaks of the pulses (601a, 601b) provided through the first pump segment and the second pump segment are approximately 180 degrees out of phase. 
Sustav prema zahtjevu 6, naznačen time, da barem jedan od najmanje dva segmenta (103) sisaljke sadrži prvi segment (1034) sisaljke 1 gdje barem jedan od sljedećeg segmenta sisaljke sadrži drugi segment (103b) sisaljke i pri čemu su odgovarajuće vršne vrijednosti pulseva (601a, 601b) dobivenih kroz prvi segment sisaljke i drugi segment sisaljke otprilike 180 stupnjeva izvan faze.
A further embodiment of the present invention relates to compounds of the formula (Ia″), where the compounds of the formula (Ia″) are compounds of the formula (I-T2) 
Spojevi prema zahtjevu 1, naznačeni time da spojevi s formulom (1a") su spojevi s formulom (I-T2) (I-T2) gdje
A process according to any one of the preceding claims, wherein the compound of formula IIa or IIb is isolated by precipitation by means of addition of isopropylether. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da se spoj s formulom Ila ili IIb izolira uz taloženje pomoću dodavanja izopropiletera.
“Halogen” or “halo” means fluorine, chlorine, bromine, or iodine. 
"halogen" ili "halo" znači fluor, klor, brom ili jod;
It should be understood that a combination of two or more fillers may be desirable, just as the particle size distribution of the filler(s) may be fairly broad in order to allow a dense packing of the filler and thereby facilitate incorporation of a high amount of fillers in the composite material. 
Valja razumjeti da može biti poželjna kombinacija dvaju ili više punila, tako da distribucija veličine čestica punila može biti prilično široka da bi se omogućilo gusto pakiranje punila i stoga olakša ugradnja velike količine punila u kompozitnom materijalu.
Second MACERS = (ST2 T2/ST2 T0 + aln(NP T2), wherein a is a weighting factor; comparing the second MACERS to the first MACERS; and determining that the treatment is efficacious in a subject having a second MACERS that is decreased as compared to the first MACERS, or that the treatment was not efficacious in a subject having a second MACERS that is equal to or elevated as compared to the first MACERS. 
(NP T2) prema slijedećoj formuli: Drugi MACERS = (ST2 T2/ST2 T0) + oln(NP T2), gde je a težinski faktor; uspoređujući drugi MACERS prema prvom MACERS; 1 određivanje da je tretman efikasan kod pacijenta koji ima drugi MACERS koji je umanjen u usporedbi sa prvim
mg or more of the nano-sized diamond and 0.0001 mg or more of the platinum nanocolloid are preferably contained in 1 kg of the fibers. 
2. < Vlakna u skladu s patentnim zahtjevom 1, naznačena time što sadrže 0,01 mg ili više navedenog dijamanta nano-veličine i 0,0001 mg ili više navedenog platinskog nanokoloida po 1 kg navedenih vlakana.
The antibody according to claim 5, wherein said antibody has an IC50 less than 500 nM as measured in BMP2-induced mineralization assay in MC3T3 cells in the presence of sclerostin. 
Protutijelo ili njegov dio koji veže antigen prema zahtjevu 5, naznačeno time da navedeno protutijelo ili njegov dio koji veže antigen ima vrijednost ICs, manju od 1 uM, poželjno manju od 500 nM i poželjnije manju od 200 nM kako je mjereno sa BMP2-induciranim testom mineralizacije kod MC3T3 stanica u prisutnosti sklerostina.
A method for preparing a compound of formula (III), or salt thereof, wherein 
"Postupak za proizvodnju spoja formule (III) ili njegove soli, O
A polymorph according to claim 2 characterised in that it provides an XRPD pattern comprising peaks as set out in Table 4: 2θ / ° d-spacing / Å 
3. > Polimorf u skladu s patentnim zahtjevom 2, naznačen time što osigurava uzorak XRPD koji sadrži maksimume kao što su iznijeti u Tablici 4: 200% | d-razmak/A
The wet granules were dried in the Fluid Bed Processor at 60° C. The dried granules were sieved through mesh #30 and blended with microcrystalline cellulose 26.45 mg (11.5% w/w), croscarmellose Sodium 3.45 mg (3% w/w), colloidal silicon dioxide 0.575 mg (0.25% w/w) pre-sifted through mesh #40 and pre-sifted magnesium stearate 2.30 mg (1% w/w). 
Vlažne granule su osušene u Fluid Bed Procesoru na 60?C. Osušene granule su prosijane kroz sito # 30 i pomiješane s mikrokristalnom celulozom 26,45 mg (11,5 % w/w), kroskarmeloza natrijem 3,45 mg (3 % w/w), koloidnim silicij dioksidom 0,575 mg (0,25 % w/w) prethodno-prosijanim kroz sito # 40 i prethodno prosijanim magnezij stearatom 2,30 mg (1 % w/w).
The composition for use according to any one of the preceding claims, wherein the compounds in said composition are formulated or administered together, separately or sequentially. 
Smjesa za uporabu prema bilo kojem od zahtjeva 1 do 6, gdje su spojevi oblikovani ili primijenjeni zajedno, odvojeno ili uzastopce.
The modular antibody according to claim 1, wherein the antibody binds to human Fc receptor CD64 The modular antibody according to claim 1 or 2, wherein the antibody binds to human FcRn receptor 
Modularno antitijelo prema patentnom zahtjevu 1, koje ima najmanje jedno od – stanično posredovana citotoksičnost zavisna od antitijela (ADCC), stanična fagocitoza zavisna od antitijela (ADCP), citotoksičnost zavisna od komplementa (CDC) ili apoptotična aktivnost. Modularno antitijelo prema patentnom zahtjevu 2, koje ima apoptotičnu aktivnost.
The method of embodiment 90 or embodiment 91, wherein step (c) comprises repeating steps (a) and (b) until lipoprotein complexes of least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% homogeneity are obtained. 
Postupak prema zahtjevu 1, naznačen time što se koraci (b) i (c) ponavljaju sve dok se najmanje 85%, najmanje 90%, ili najmanje 95% proteinske komponente je ugrađeno u lipoproteinske komplekse.